The GTPase function of LRRK2

Biochemical Society Transactions

Volumn 40, Issue 5, 2012, Pages 1063-1069

  Taymans, Jean Marc ^a  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

G protein cycle; GTPase; Leucine rich repeat kinase 2 (LRRK2); Parkinson's disease; Ras of complex proteins (ROC)

Indexed keywords

CELL PROTEIN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2;

AMINO ACID SEQUENCE; CELL FUNCTION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

GTP PHOSPHOHYDROLASES; HUMANS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EUKARYOTA;

EID: 84866652723     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120133     Document Type: Review

References (62)

1. Bosgraaf, L. and Van Haastert, P.J. (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643, 5-10
2. Marin, I. (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 23, 2423-2433
3. Marin, I., van Egmond, W.N. and van Haastert, P.J. (2008) The Roco protein family: a functional perspective. FASEB J. 22, 3103-3110
4. Nuytemans, K., Rademakers, R., Theuns, J., Pals, P., Engelborghs, S., Pickut, B., de Pooter, T., Peeters, K., Mattheijssens, M., Van den Broeck, M. et al. (2008) Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur. J. Hum. Genet. 16, 471-479
5. Zabetian, C.P., Samii, A., Mosley, A.D., Roberts, J.W., Leis, B.C., Yearout, D., Raskind, W.H. and Griffith, A. (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65, 741-744
6. Paisán-Ruíz, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., van der Brug, M., López de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
7. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
8. Aasly, J.O., Vilarino-Guell, C., Dachsel, J.C., Webber, P.J., West, A.B., Haugarvoll, K., Johansen, K.K., Toft, M., Nutt, J.G., Payami, H. et al. (2010) Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov. Disord. 25, 2156-2163
9. Rubio, J.P., Topp, S., Warren, L., St Jean, P.L., Wegmann, D., Kessner, D., Novembre, J., Shen, J., Fraser, D., Aponte, J. et al. (2012) Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. Hum. Mutat. 33, 1087-1098
10. Gasser, T. (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med. 11, e22
11. Paisán-Ruíz, C. (2009) LRRK2 gene variation and its contribution to Parkinson disease. Hum. Mutat. 30, 1153-1160
12. Bourne, H.R., Sanders, D.A. and McCormick, F. (1991) The GTPase superfamily: conserved structure and molecular mechanism. Nature 349, 117-127
13. Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J.-M., Daniels, V., Lewis, P., Jain, S., Ding, J., Syed, A. et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283, 16906-16914
14. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380-1388
15. Taymans, J.-M., Vancraenenbroeck, R., Ollikainen, P., Beilina, A., Lobbestael, E., De Maeyer, M., Baekelandt, V. and Cookson, M.R. (2011) LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS ONE 6, e23207
16. Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M. and Moore, D.J. (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 6, e1000902
17. Li, Y., Dunn, L., Greggio, E., Krumm, B., Jackson, G.S., Cookson, M.R., Lewis, P.A. and Deng, J. (2009) The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim. Biophys. Acta 1792, 1194-1197
18. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232
19. Daniëls, V., Vancraenenbroeck, R., Law, B.M., Greggio, E., Lobbestael, E., Gao, F., De Maeyer, M., Cookson, M.R., Harvey, K., Baekelandt, V. and Taymans, J.-M. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem. 116, 304-315
20. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A. and Cookson, M.R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671
21. Guo, L., Gandhi, P.N., Wang, W., Petersen, R.B., Wilson-Delfosse, A.L. and Chen, S.G. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 313, 3658-3670
22. Li, X., Tan, Y.C., Poulose, S., Olanow, C.W., Huang, X.Y. and Yue, Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103, 238-247
23. Pungaliya, P.P., Bai, Y., Lipinski, K., Anand, V.S., Sen, S., Brown, E.L., Bates, B., Reinhart, P.H., West, A.B., Hirst, W.D. and Braithwaite, S.P. (2010) Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS ONE 5, e13672
24. Liu, M., Dobson, B., Glicksman, M.A., Yue, Z. and Stein, R.L. (2010) Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 49, 2008-2017
25. Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A.D., Gerber, S.A., Cuny, G.D. and Glicksman, M.A. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry 50, 9399-9408
26. Taymans, J.-M. and Cookson, M. (2010) Mechanisms of dominant parkinsonism; the toxic triangle of LRRK2, α-synuclein and tau. BioEssays 32, 227-235
27. Gotthardt, K., Weyand, M., Kortholt, A., Van Haastert, P.J. and Wittinghofer, A. (2008) Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J. 27, 2352
28. McKay, M.M. and Morrison, D.K. (2007) Integrating signals from RTKs to ERK/MAPK. Oncogene 26, 3113-3121
29. Herrmann, C., Martin, G.A. and Wittinghofer, A. (1995) Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J. Biol. Chem. 270, 2901-2905
30. Deng, J., Lewis, P.A., Greggio, E., Sluch, E., Beilina, A. and Cookson, M.R. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U.S.A. 105, 1499-1504
31. Klein, C.L., Rovelli, G., Springer, W., Schall, C., Gasser, T. and Kahle, P.J. (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J. Neurochem. 111, 703-715
32. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A. and Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307-317
33. Greggio, E., Taymans, J.-M., Zhen, E.Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V. et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 389, 449-454
34. Gloeckner, C.J., Boldt, K., von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu, H. and Ueffing, M. (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J. Proteome Res. 9, 1738-1745
35. Webber, P.J., Smith, A.D., Sen, S., Renfrow, M.B., Mobley, J.A. and West, A.B. (2011) Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J. Mol. Biol. 412, 94-110
36. Kamikawaji, S., Ito, G. and Iwatsubo, T. (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963-10975
37. Doggett, E.A., Zhao, J., Mork, C.N., Hu, D. and Nichols, R.J. (2012) Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. J. Neurochem. 120, 37-45
38. Nichols, R.J., Dzamko, N., Morrice, N.A., Campbell, D.G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A.R. and Alessi, D.R. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393-404
39. Wittinghofer, A. and Vetter, I.R. (2011) Structure-function relationships of the G domain, a canonical switch motif. Annu. Rev. Biochem. 80, 943-971
40. Rossman, K.L., Der, C.J. and Sondek, J. (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6, 167-180
41. Cherfils, J. and Chardin, P. (1999) GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem. Sci. 24, 306-311
42. Christoforidis, S. and Zerial, M. (2000) Purification and identification of novel Rab effectors using affinity chromatography. Methods 20, 403-410
43. Hart, M.J., Sharma, S., elMasry, N., Qiu, R.G., McCabe, P., Polakis, P. and Bollag, G. (1996) Identification of a novel guanine nucleotide exchange factor for the Rho GTPase. J. Biol. Chem. 271, 25452-25458
44. Häbig, K., Walter, M., Poths, S., Riess, O. and Bonin, M. (2007) RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9, 83-94
45. Fukuhara, S., Chikumi, H. and Gutkind, J.S. (2000) Leukemia-associated Rho guanine nucleotide exchange factor (LARG) links heterotrimeric G proteins of the G12 family to Rho. FEBS Lett. 485, 183-188
46. Feng, Q., Albeck, J.G., Cerione, R.A. and Yang, W. (2002) Regulation of the Cool/Pix proteins: key binding partners of the Cdc42/Rac targets, the p21-activated kinases. J. Biol. Chem. 277, 5644-5650
47. Manser, E., Loo, T.H., Koh, C.G., Zhao, Z.S., Chen, X.Q., Tan, L., Tan, I., Leung, T. and Lim, L. (1998) PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. Mol. Cell 1, 183-192
48. Reid, T., Bathoorn, A., Ahmadian, M.R. and Collard, J.G. (1999) Identification and characterization of hPEM-2, a guanine nucleotide exchange factor specific for Cdc42. J. Biol. Chem. 274, 33587-33593
49. Haebig, K., Gloeckner, C.J., Miralles, M.G., Gillardon, F., Schulte, C., Riess, O., Ueffing, M., Biskup, S. and Bonin, M. (2010) ARHGEF7 (β-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS ONE 5, e13762
50. Furman, C., Short, S.M., Subramanian, R.R., Zetter, B.R. and Roberts, T.M. (2002) DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism. J. Biol. Chem. 277, 7962-7969
51. Cukierman, E., Huber, I., Rotman, M. and Cassel, D. (1995) The ARF1 GTPase-activating protein: zinc finger motif and Golgi complex localization. Science 270, 1999-2002
52. Stafa, K., Trancikova, A., Webber, P.J., Glauser, L., West, A.B. and Moore, D.J. (2012) GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 8, e1002526
53. Xiong, Y., Yuan, C., Chen, R., Dawson, T.M. and Dawson, V.L. (2012) ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J. Neurosci. 32, 3877-3886
54. Gasper, R., Meyer, S., Gotthardt, K., Sirajuddin, M. and Wittinghofer, A. (2009) It takes two to tango: regulation of G proteins by dimerization. Nat. Rev. Mol. Cell Biol. 10, 423-429
55. Daniëls, V., Baekelandt, V. and Taymans, J.-M. (2011) On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies. Neurosignals 19, 1-15
56. Ding, X. and Goldberg, M.S. (2009) Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS ONE 4, e5949
57. Ko, H.S., Bailey, R., Smith, W.W., Liu, Z., Shin, J.H., Lee, Y.I., Zhang, Y.J., Jiang, H., Ross, C.A., Moore, D.J. et al. (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc. Natl. Acad. Sci. U.S.A. 106, 2897-2902
58. Sancho, R.M., Law, B.M. and Harvey, K. (2009) Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum. Mol. Genet. 18, 3955-3968
59. Gandhi, P.N., Wang, X., Zhu, X., Chen, S.G. and Wilson-Delfosse, A.L. (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86, 1711-1720
60. Vancraenenbroeck, R., Lobbestael, E., De Maeyer, M., Baekelandt, V. and Taymans, J.-M. (2011) Kinases as targets for Parkinson's disease; from genetics to therapy. CNS Neurol. Disord.: Drug Targets 10, 724-740
61. Greggio, E. and Singleton, A. (2007) Kinase signaling pathways as potential targets in the treatment of Parkinson's disease. Expert Rev. Proteomics 4, 783-792
62. Rudenko, I.N., Chia, R. and Cookson, M.R. (2012) Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med. 10, 20